Search research articles
Contact Us
Filters
Showing results (71-80 of 78) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 78 results.
HIV Medicine
|
February 12, 2009
Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy
H Byakwaga, J Zhou, K Petoumenos, et al.
Journal of Applied Microbiology
|
January 30, 2015
Adaptation of red blood cell lysis represents a fundamental breakthrough that improves the sensitivity of Salmonella detection in blood
M A Boyd, S M Tennant, J H Melendez, et al.
HIV Medicine
|
November 5, 2005
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009
M A Boyd, U Siangphoe, K Ruxrungtham, et al.
Cancer Treatment Reports
|
November 1, 1986
Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase
D C Case, H L Sonneborn, S D Paul, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 18, 2014
Is it time to rethink syphilis control?
M A Boyd, B Donovan, G Prestage, et al.
HIV Medicine
|
April 17, 2014
A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy
A D Revell, M A Boyd, D Wang, et al.
Lancet (London, England)
|
June 18, 2013
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
, M A Boyd, N Kumarasamy, et al.
Journal of the International Association of Providers of AIDS Care
|
February 21, 2013
Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database
H Byakwaga, K Petoumenos, J Ananworanich, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 78) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 78 results.
HIV Medicine
|
February 12, 2009
Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy
H Byakwaga, J Zhou, K Petoumenos, et al.
Journal of Applied Microbiology
|
January 30, 2015
Adaptation of red blood cell lysis represents a fundamental breakthrough that improves the sensitivity of Salmonella detection in blood
M A Boyd, S M Tennant, J H Melendez, et al.
HIV Medicine
|
November 5, 2005
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009
M A Boyd, U Siangphoe, K Ruxrungtham, et al.
Cancer Treatment Reports
|
November 1, 1986
Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase
D C Case, H L Sonneborn, S D Paul, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 18, 2014
Is it time to rethink syphilis control?
M A Boyd, B Donovan, G Prestage, et al.
HIV Medicine
|
April 17, 2014
A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy
A D Revell, M A Boyd, D Wang, et al.
Lancet (London, England)
|
June 18, 2013
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study
, M A Boyd, N Kumarasamy, et al.
Journal of the International Association of Providers of AIDS Care
|
February 21, 2013
Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database
H Byakwaga, K Petoumenos, J Ananworanich, et al.
Page
of 8